Skip to main content

AC Immune SA

corporate_fare Company Profile

AC Immune SA

ACIU·NASDAQ·Life Sciences·CIK 0001651625

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA (NASDAQ:ACIU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ACIU at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ACIU spans 6-K, 20-F.

Recent high-impact activity:

  • AC Immune Posts 13-Cent Quarterly Loss, Cash Runs Into 2028
  • AC Immune Q3: CHF 73.9M Cash, Runway Into Q1 2028, Loss Narrowed to CHF 8.8M
  • AC Immune's Parkinson's Vaccine Hits All Primary Endpoints in Phase 2 Part 1
  • AC Immune's ACI-7104 Hits All Primary Endpoints in Phase 2 Parkinson's Trial
  • AC Immune's NLRP3 Inhibitor Shows Brain Penetration, Advances to Phase 1b

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
CHF 3.57M CHF
Net Income
-CHF 70.45M CHF
Diluted EPS
-CHF 0.70 CHF
Op. Cash Flow
-CHF 69.26M CHF
Free Cash Flow
-CHF 70.16M CHF
Operating Income
-CHF 69.32M CHF
Cash & Equivalents
CHF 26.8M CHF
Debt / Equity
0.00×
Net Margin
-19.72×
Source: 20-F · filed 2026-03-13 · accession 0001104659-26-027342

Short Interest & Short Volume

16.88 days to cover

FINRA reported short interest of 2,947,102 shares in ACIU as of the October 30, 2026 settlement, a 9.7% decrease from the prior period — about 16.9 days to cover at its recent average daily volume. On November 20, 2026, 56.0% of ACIU volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,947,102 shares as of October 30, 2026
Change vs prior period▼ 9.7%
Days to cover16.88 at avg daily volume of 174,567
Daily short volume (FINRA facilities)56.0% of 139,791 shares on November 20, 2026
5-day average short volume59.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

ACIU files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with A →
$1.95
52-week range · as of 2026-11-04 $1.95 – $3.9
Market cap
$198.46M
Volume
298.4K (1.5× avg)
3-mo avg 205.2K
Live data · 2026-11-21 03:37 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ACIU - Latest Insights

ACIU
Nov 04, 2026, 7:01 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $1.95 info
Change: -$0.210 (-10%) info
Market Cap: $198.458M info
ACIU
Nov 04, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $1.95 info
Change: -$0.210 (-10%) info
Market Cap: $198.458M info
ACIU
Sep 23, 2026, 7:01 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.73
Real-time Price: $1.95 info
Change: -$0.780 (-29%) info
Market Cap: $198.458M info
ACIU
Sep 23, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.73
Real-time Price: $1.95 info
Change: -$0.780 (-29%) info
Market Cap: $198.458M info
ACIU
Aug 20, 2026, 12:32 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $2.53
Real-time Price: $1.95 info
Change: -$0.575 (-23%) info
Market Cap: $198.458M info
ACIU
Aug 20, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.64
Real-time Price: $1.95 info
Change: -$0.690 (-26%) info
Market Cap: $198.458M info
ACIU
Aug 11, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.37
Real-time Price: $1.95 info
Change: -$0.4163 (-18%) info
Market Cap: $198.458M info
ACIU
Aug 05, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.23
Real-time Price: $1.95 info
Change: -$0.280 (-13%) info
Market Cap: $198.458M info
ACIU
Jun 30, 2026, 9:03 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.36
Real-time Price: $1.95 info
Change: -$0.410 (-17%) info
Market Cap: $198.458M info
ACIU
Jun 11, 2026, 4:53 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.26
Real-time Price: $1.95 info
Change: -$0.3101 (-14%) info
Market Cap: $198.458M info
ACIU
Jun 11, 2026, 7:15 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.95 info
Change: -$0.230 (-11%) info
Market Cap: $198.458M info
ACIU
Jun 11, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $2.22
Real-time Price: $1.95 info
Change: -$0.270 (-12%) info
Market Cap: $198.458M info
ACIU
May 15, 2026, 9:17 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.80
Real-time Price: $1.95 info
Change: -$0.850 (-30%) info
Market Cap: $198.458M info
ACIU
May 12, 2026, 8:13 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.85
Real-time Price: $1.95 info
Change: -$0.8999 (-32%) info
Market Cap: $198.458M info
ACIU
Apr 30, 2026, 7:09 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.02
Real-time Price: $1.95 info
Change: -$1.07 (-35%) info
Market Cap: $198.458M info
ACIU
Apr 30, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $1.95 info
Change: -$1.07 (-35%) info
Market Cap: $198.458M info
ACIU
Apr 07, 2026, 7:33 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $2.79
Real-time Price: $1.95 info
Change: -$0.840 (-30%) info
Market Cap: $198.458M info
ACIU
Apr 07, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.85
Real-time Price: $1.95 info
Change: -$0.900 (-32%) info
Market Cap: $198.458M info
ACIU
Mar 13, 2026, 7:00 AM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $2.90
Real-time Price: $1.95 info
Change: -$0.950 (-33%) info
Market Cap: $198.458M info
ACIU
Mar 13, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.90
Real-time Price: $1.95 info
Change: -$0.950 (-33%) info
Market Cap: $198.458M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets